Introducing Endpoints FDA+, our new premium weekly regulatory news report led by Zachary Brennan
CRLs. 483s. CBER, CDER and RWE. For biopharma professionals, these acronyms command attention because of the fundamental role FDA plays in drug development. Now Endpoints is doubling down on regulatory coverage, and launching a weekly report focusing on developments out of White Oak, with analysis and insight into what it all means.
Coverage will be led by our new senior editor, Zachary Brennan. He joins Endpoints from POLITICO, where he covered pharma. Prior to that he was the managing editor for Regulatory Focus, a news publication from the Regulatory Affairs Professionals Society.
This new regulatory beat is part of our commitment to going deeper and broader in 2021. The main Endpoints News website and daily news report covers the entire watershed of biopharma from drug discovery to approvals, with a laser focus on clinical R&D. Back in January we launched Endpoints Manufacturing, which you can sign up for here for a deeper exploration into supply chains and biomanufacturing.
Endpoints FDA+ will focus on FDA but we’ll also look at consequential developments coming out of other major regulatory authorities like EMA and China FDA. We’ll give you the news, the context around it, what it means for biopharma and who it impacts.
For premium subscribers on either an Enterprise or Insider plan, there’s no additional charge to access Endpoints FDA+ stories or to sign up for the weekly email report, which launches in April.
Zachary Brennan starts at Endpoints on Monday, March 8. Please give him a warm welcome, you can contact him at: email@example.com.